• 1. An analyte-triggered artificial peroxidase system based on dimanganese complex for a versatile enzyme assay?
  Suji Lee,Min Su Han Chem. Commun., 2021,57, 9450-9453
• 2. An atlas of endohedral Sc2S cluster fullerenes?
  Li-Hua Gan,Rui Wu,Jian-Lei Tian,Patrick W. Fowler Phys. Chem. Chem. Phys., 2017,19, 419-425
• 3. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 4. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 5. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554

Professional Introduction to Compound with CAS No. 1325205-45-5 and Product Name: 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine

The compound identified by the CAS number 1325205-45-5 and the product name 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic compound, featuring a fused thiophene and pyrazole ring system, has garnered considerable attention due to its unique structural properties and potential biological activities. The molecular architecture of this compound incorporates an ethylthiophenyl moiety at the 5-position of the pyrazole ring, which is a key feature that contributes to its distinct chemical and pharmacological characteristics.

In recent years, there has been a growing interest in developing novel therapeutic agents based on heterocyclic compounds. These molecules often exhibit favorable pharmacokinetic properties and can interact with biological targets in unique ways. The 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine structure combines the advantages of both the thiophene and pyrazole scaffolds, which are well-documented for their role in various pharmacological applications. The thiophene ring, in particular, is known for its presence in numerous bioactive natural products and pharmaceuticals, while the pyrazole ring is a common motif in drugs targeting inflammatory and immunomodulatory pathways.

One of the most compelling aspects of this compound is its potential as a scaffold for drug discovery. The presence of the ethylthiophenyl group introduces a region of electronic richness and reactivity, which can be exploited for designing molecules with enhanced binding affinity to biological targets. This feature has been particularly explored in the development of kinase inhibitors, where thiophene-based compounds have shown promise due to their ability to modulate enzyme activity effectively. The pyrazole moiety further enhances the compound's potential by providing a platform for further functionalization, allowing chemists to tailor properties such as solubility, metabolic stability, and target specificity.

Recent studies have highlighted the importance of 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine in medicinal chemistry research. Researchers have demonstrated its utility as a precursor in synthesizing more complex derivatives that exhibit improved pharmacological profiles. For instance, modifications to the ethylthiophenyl group have led to compounds with enhanced activity against certain cancer cell lines. These derivatives have shown promise in preclinical studies, particularly in terms of inhibiting proliferation and inducing apoptosis in tumor cells. The pyrazole ring has also been modified to introduce additional functional groups that enhance interactions with biological targets, leading to more potent and selective drug candidates.

The synthesis of 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine involves multi-step organic reactions that showcase the versatility of modern synthetic methodologies. The process typically begins with the preparation of key intermediates such as 5ethylthiophene-2-carbaldehyde and 1H-pyrazol-5-carboxamide. These intermediates are then coupled using palladium-catalyzed cross-coupling reactions, which provide a high degree of selectivity and yield under optimized conditions. The final product is obtained through subsequent functional group transformations, including reduction and condensation steps that establish the desired connectivity between the thiophene and pyrazole rings.

The pharmacological evaluation of 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine has revealed several interesting properties that make it a valuable candidate for further development. In vitro studies have indicated that this compound exhibits moderate activity against various enzymes and receptors relevant to human health. Notably, it has shown inhibitory effects on certain kinases that are implicated in inflammatory diseases and cancer progression. Additionally, preliminary toxicology studies suggest that the compound is well-tolerated at tested doses, although further investigation is warranted to fully assess its safety profile.

The potential applications of 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine extend beyond oncology. Researchers are exploring its use in treating inflammatory disorders by targeting pathways involved in immune responses. The structural features of this compound allow it to interact with multiple biological targets simultaneously, which could lead to synergistic therapeutic effects. Furthermore, its ability to cross the blood-brain barrier makes it an attractive candidate for developing treatments for neurological conditions such as Alzheimer's disease and Parkinson's disease.

In conclusion, 3-(5-Ethylthiophen-2-yl)-1H-pyrazol-5-amine (CAS No. 1325205-45-5) represents a promising entity in pharmaceutical research due to its unique structural features and potential biological activities. The combination of a thiophene ring with an ethyl substituent at one position and a pyrazole ring at another creates a versatile scaffold that can be modified to develop novel therapeutic agents. Ongoing research continues to uncover new applications for this compound, particularly in oncology and inflammation management. As our understanding of its pharmacological properties grows, so too does its potential as a lead compound for future drug development efforts.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)